Topical Preparation of Pomegranate and Ginkgo Biloba for Anti-aging Activities

NCT03772418 | Unknown Phase 1 DMC

• 1 other identifier: AlAzharPGB
• Study Type: interventional
• Target: 30
• Locations: 2 countries
• Sites: 3

Brief Summary

As the quality of life improves, people are seeking to look as young as they feel. Ginkgo biloba (GB) and Pomegranate (PG) extract can be used to create efficacious topical anti-aging products. GB \& PG are now widely used in research and clinical trials on age-associated diseases, for example, skin aging, brain dysfunction, cardiovascular system diseases, carcinogen metabolism. The investigator's aim is to formulate a topical cream in the form (O/W or W/O emulsion) formulation, containing GB as an anti-aging formulation for the public.

Conditions

Skin and Subcutaneous Tissue Disorders

Outcome Measures

Primary Outcomes (1)

• Measurement of ant-aging activity of Pomegranate and Ginkgo biloba

  The crow's feet wrinkle of 17 volunteers will be measured compared to the control group. The significant results will measure the decrease in the depths of deep furrows for groups treated with Pomegranate and Ginkgo biloba over a three months period.

  Three months

Secondary Outcomes (1)

• Stable topical anti-aging products for long life shelf storage

  Six months

Study Arms (2)

Cream base

PLACEBO COMPARATOR

A group of volunteers receiving placebo medications without natural extracts of ginkgo biloba and Pomegranate.

Drug: Cream Base

Pomegrante and Ginkgo biloba group

ACTIVE COMPARATOR

A group of volunteers with the aging state receiving natural extracts of ginkgo biloba and Pomegranate in different topical dosage forms.

Drug: Pomegrante and Ginkgo biloba group

Interventions

Cream Base DRUG

The formulated dosage form without ginkgo biloba or pomegranate will be applied to the 30 aging people who are suffering from wrinkles in the skin male and female. Typically, will be applied on two groups, one man (Group 0a) and one woman were (Group 0b) which they will be used plain cream.

Also known as: Aging group recieving placebo dosage form

Cream base

Pomegrante and Ginkgo biloba group DRUG

The extracts of ginkgo biloba and Pomegranate as formulated in topical dosage form will be applied to the 30 aging people who are suffering from wrinkles in the skin male and female. Formulated cream will be applied on two groups, one man (Group Ia)and one woman (Group Ib).

Also known as: Aging group receive ginkgo biloba and Pomegranate

Pomegrante and Ginkgo biloba group

Eligibility Criteria

• Age: 50 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Clinical diagnosis of aging shape
• Follow up and collect data for a local and systemic activity of Ginkgo Biloba and Pomegranate
• The skin should be not injured as the cream can be easily applied
• Systemic oral capsule Ginkgo Biloba and Pomegranate can be also given to enhance the activity as anti-aging activity

You may not qualify if:

• Insulin-dependent diabetes
• Hypertension disease
• Skin wound

Sponsors & Collaborators

• Ahmed A. H. Abdellatif: lead

Study Sites (3)

Assiut Clinic

Asyut, 71526, Egypt

RECRUITING

Faculty of Pharmacy

Buraidah, Al-Qassim Region, 51452, Saudi Arabia

RECRUITING

Pharmaceutics dept., Faculty of Pharmacy, Qassim University

Buraidah, Al-Qassim Region, 51452, Saudi Arabia

RECRUITING

Related Publications (3)

• Dong LY, Fan L, Li GF, Guo Y, Pan J, Chen ZW. [Anti-aging action of the total lactones of ginkgo on aging mice]. Yao Xue Xue Bao. 2004 Mar;39(3):176-9. Chinese.

  PMID: 15171650 BACKGROUND

• Kang SJ, Choi BR, Kim SH, Yi HY, Park HR, Song CH, Ku SK, Lee YJ. Beneficial effects of dried pomegranate juice concentrated powder on ultraviolet B-induced skin photoaging in hairless mice. Exp Ther Med. 2017 Aug;14(2):1023-1036. doi: 10.3892/etm.2017.4626. Epub 2017 Jun 16.

  PMID: 28810554 BACKGROUND

• Rasul A, Akhtar N. Formulation and in vivo evaluation for anti-aging effects of an emulsion containing basil extract using non- invasive biophysical techniques. Daru. 2011;19(5):344-50.

  PMID: 22615680 RESULT

MeSH Terms

Conditions

Skin Diseases

Condition Hierarchy (Ancestors)

Skin and Connective Tissue Diseases

Study Officials

• Ahmed Abdellatif, Ph.D.

  Assistant Prof. at Pharmaceutics dept., Faculty of Pharmacy, Qassim University, KSA

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Ahmed AH Abdellatif, Ph.D.

CONTACT

+966507726856; a.abdellatif@qu.edu.sa

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Assistant Prof. at Pharmaceutics dept., Faculty of Pharmacy, Qassim University, KSA

Study Record Dates

• First Submitted: May 15, 2018
• First Posted: December 11, 2018
• Study Start: May 18, 2018
• Primary Completion: January 1, 2020
• Study Completion: February 28, 2020
• Last Updated: December 11, 2018

Record last verified: 2018-12

Locations

SA (2); EG (1)